USE OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR IS ASSOCIATED WITH LOW RISK OF HEPATIC DECOMPENSATIONS BUT IS NOT AFFECTING DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN TYPE II DIABETES PATIENTS.

被引：0

作者：

Kim, Heaeun ^{[1
]}

Kim, Jin-Wook ^{[1
]}

Park, Jaewon ^{[1
]}

Jang, Sangmi ^{[2
]}

Jeong, Chan Young ^{[1
]}

Choi, Gwang Hyeon ^{[1
]}

Jang, Eun Sun ^{[1
]}

Jeong, Sook-Hyang ^{[1
]}

机构：

[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seoul, South Korea

[2] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

来源：

HEPATOLOGY | 2021年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1895

引用

页码：1127A / 1128A

页数：2

共 50 条

[1] Sodium-glucose co-transporter-2 inhibitors and the risk of fractures in patients with type 2 diabetes
Schmedt, Niklas
Andersohn, Frank
Walker, Jochen
Garbe, Edeltraut
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 454 - 454
[2] SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR USE IN THE MANAGEMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES MELLITUS
Alzetani, Sarah
Suresh, Vijayan
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I690 - I691
[3] Clinical use of sodium-glucose co-transporter-2 inhibitors in Chinese patients with type 2 diabetes mellitus
Chan, Wing Bun
SINGAPORE MEDICAL JOURNAL, 2019, 60 (06) : 309 - 313
[4] A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus
Avogaro, A.
Giaccari, A.
Fioretto, P.
Genovese, S.
Purrello, F.
Giorgino, F.
Del Prato, S.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (07) : 763 - 772
[5] Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
Dekkers, Claire C. J.
Sjostrom, C. David
Greasley, Peter J.
Cain, Valerie
Boulton, David W.
Heerspink, Hiddo J. L.
DIABETES OBESITY & METABOLISM, 2019, 21 (12): : 2667 - 2673
[6] Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
Washburn, William N.
Poucher, Simon M.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (04) : 463 - 486
[7] RISK OF NEW-ONSET ACUTE ISCHEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES ON SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR USERS
Jong, G. -P.
Yang, T. -Y.
INTERNATIONAL JOURNAL OF STROKE, 2023, 18 (03) : 312 - 312
[8] Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology
Gangat, Naseema
Tefferi, Ayalew
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (12) : 2670 - 2672
[9] Risk of incident renal cell carcinoma in patients with type 2 diabetes on sodium-glucose co-transporter-2 inhibitor users: a population-based cohort study
Jong, G. P.
Yang, T. Y.
EUROPEAN HEART JOURNAL, 2023, 44
[10] Sodium-glucose co-transporter-2 inhibitors in Type 1 Diabetes: A Scoping Review
Hropot, Tim
Battelino, Tadej
Dovc, Klemen
HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 (06): : 620 - 630

← 1 2 3 4 5 →